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Abstract Treating spontaneously hypertensive rats (SHR)
with L-arginine, taurine, and vitamins C and E (ATCE)
during nephrogenesis (2 weeks before to 4 weeks after
birth) persistently lowers blood pressure. Hypothetically,
differential gene expression in kidney of SHR vs. normo-
tensive Wistar–Kyoto rats (WKY) is partially corrected by
maternal ATCE in SHR. Differential gene expression in 2-
days, 2-weeks, and 48-week-old rats was studied using
oligonucleotide chips. Transcription factor binding sites
(TFBS) of differentially expressed genes were analyzed in
silico. Differential gene expression varied between SHR+
ATCE and SHR, suggesting both direct and indirect
effects; but, few genes were modulated toward WKY level
and there was little overlap between ages. TFBS analysis
suggests less Elk-1-driven gene transcription in both WKY
and SHR+ATCE vs. SHR at 2 days and 2 weeks.
Concluding, in SHR, persistent antihypertensive effects of
maternal ATCE are not primarily due to persistent correc-
tive transcription. Less Elk-1-driven transcription at 2 days
and 2 weeks may be involved.
Keywords Development.Geneexpression.
Hypertensiverats.Kidney.Transcriptionfactorbindingsites
Introduction
Transplantation studies indicate that blood pressure “fol-
lows” the kidney [16, 25, 43] and all monogenic forms of
hypertension have a renal origin [30]. In studies reporting
on the renal transcriptome in SHR [19, 33, 35, 41], the
earliest time point studied was 3–4 weeks of age [19, 41].
This is commonly termed the prehypertensive stage, a
disputable term since small differences in blood pressure
may not be detectable at this age [26]. At 2 days, the rat
kidney contains at least 26 terminally differentiated cell
types, recognizable by morphology, location, and function
[2]. At 2 weeks, renal vascular and nephron development is
complete [17, 31]. Even by 1 year, there is little renal injury
in male SHR [10] and practically none in female SHR [9].
We previously reported persistent reduction of hyperten-
sion up to 48 weeks of age in offspring of SHR dams that
were perinatally treated with a combination of L-arginine
and antioxidants (taurine, vitamins C and E; ATCE) in the
last 2 weeks of pregnancy and up to 4 weeks of lactation
[39]. This alleviation of hypertension could be related to
differences between the renal transcriptome of perinatally
treated and untreated SHR. Hence, we hypothesized that
differential gene expression in suckling 2 days and 2 weeks
SHR vs. age-matched normotensive Wistar–Kyoto rats
(WKY) would be partially corrected by maternal treatment
with ATCE in SHR.
Primary objectives were to identify differential gene
expression in suckling newborn (2 days) and 2-week-old
SHR vs. WKY and associated transcription factor bindings
sites (TFBS) to ascertain whether partial correction of this
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Edmonton, AB, Canadadifferential expression occurred with maternal treatment of
SHR with ATCE and, if so, whether this partial correction
involved the same associated TFBS. The TFBS were
identified using in silico techniques. A secondary objective
was to determine whether consistent differential gene
expression and associated TFBS occurring in very young
(prehypertensive) SHR vs. WKY persisted at 48 weeks in
SHR vs. WKY and to ascertain whether these persistent
variables were also persistently affected in SHR by
maternal treatment with ATCE.
Materials and methods
Breeding and supplement protocol
Untreated SHR and normotensive Wistar–Kyoto rats (WKY;
Harlan, Horst, The Netherlands) were kept under standard
conditions and were fed non-synthetic rodent chow (Special
Diets Services, Witham, Essex, England). SHR dams were
perinatally treated with L-arginine, taurine, and vitamins C
and E in the last 2 weeks of pregnancy and the first 4 weeks
of lactation in order to increase NO and reduce oxidative
stress during nephrogenesis. Female offspring of these
treated SHR dams were used in the present study (SHR
+ATCE). L-arginine, taurine, and vitamin C were dissolved
in drinking water at doses of 20 g/L, 25 g/L, and 594 mg/L,
respectively. Vitamin E was mixed in finely grounded chow
(9 g/kg) that contained 2 and 82 mg/kg vitamins C and E,
respectively. No difference was found in intake of food and
water between treated and untreated rats (data not shown).
Sentinel animals, housed under the same conditions, were
regularly monitored for infections. All rats were housed in
the same room under automated temperature control and a
12/12 h light/dark cycle. The Utrecht University Board for
studies in experimental animals approved the protocol. Adult
SHR and WKY females were mated with adult males from
the same strain and supplier. At age of 2 days, the female
pups were killed by decapitation, and at age of 2 and
48 weeks, the female rats were exsanguinated under
pentobarbital anesthesia.
Total RNA isolation, microarray procedures, and analysis
Although kidneys are highly inhomogeneous, no differences
in morphology and structure were found between rats of the
same age (data not shown). To achieve homogeneity, the
renal cortex of the adult kidney was collected from the poles
of the kidney and snap frozen. However, in the pups,
separation of cortex and medulla was not clear. Thus, the
whole and half of the kidney was taken from 2-day and 2-
week-old rats, respectively. Details of the procedures are
available in Web Appendix (http://www.nephrogenomics.
net/data/appendices/SHR-Development/). In short, total
RNA was extracted (TRIzol™) from frozen samples. The
RNA was stored at −80°C in distilled H2O. For microarray
analysis, total RNA was pooled per group at each age in
equal amounts per subject. At 2 days, 2 weeks, and 48 weeks
of age, we studied WKY (n=6,n=6,andn=8,respectively),
SHR (n=6, n=5, and n=12), and SHR+ATCE (n=6, n=5,
and n=6). Total RNA was reverse-transcribed (RT) with
allyl-dUTP incorporation and labeled with Cy3 or Cy5 dyes
(Amersham Biosciences, Piscataway, NJ, USA). Samples
were hybridized to rat 7.5k Oligo Chips manufactured in the
Genomics Laboratory, University Medical Center Utrecht,
containing Rat Genome Array-Ready Oligo Set Version 1.1
of Qiagen-Operon [46], spotted in duplicate. Samples of
WKY or SHR+ATCE were compared to age-matched
untreated SHR and a dye switch procedure was applied
[29]. SHR Cy3- and Cy5-labeled cDNA were also
compared to allow elimination of unreliable spots. After
washing, slides were stored in the dark until scanning
using Agilent Scanner (BioDiscovery, El Segundo, CA,
USA). Images were quantified using ImaGene Software
(BioDiscovery) and data were normalized as described
previously [29]. Duplicates of the genes were averaged. A
ratio of a spot is defined as log2(Cy5/Cy3). Microarray
data of SHR vs. SHR consisted of six arrays (control
arrays). We used the average ratios and standard deviation
(SD=0.189) of the six control arrays to determine which
genes were considered for the analyses.
To define the significanceof ratio, we set the cutoff atthree
times SD. Considering the fact that statistics cannot be
performed on treated vs. untreated because they were
hybridized together on a single slide, the cutoff was set at a
higher stringency level, 0.7. Thus, a ratio of >0.7 or <−0.7
were considered significant. The z test for two proportions
indicated that a spot may have two out of six ratios >0.7
or <−0.7 before being indicated as unreliable. Out of 5,889
spots, 5,614 were considered reliable. Only the reliable spots,
determined as described above, were used in data analysis.
Considering the fact that homogeneity of kidneys may vary
between ages, we compared the SHR samples to age-
matched WKY samples. Thus, the reliable genes in WKY
and SHR+ATCE compared to age-matched untreated SHR
with a ratio of >0.7 or <−0.7 were considered differentially
expressed. Microarray data were submitted to MIAME
(EMBL-EBI) with accession numbers for array (A-MEXP-
562) and experiment (E-MEXP-1550).
Clustering analysis
Hierarchical clustering of microarray data was performed
using the Expression Profile data CLUSTering and analysis
(EPCLUST, http://www.bioinf.ebc.ee/EP/EP/). Average
linkage (average distance, UPGMA) clustering based on
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for ratios >0.7 or <−0.7.
Identification of genes with consistent differential expression
Observing genes at each age in WKY as compared to age-
matched untreated SHR revealed more than 700 differen-
tially expressed genes. We evaluated whether and for how
many of these genes this was consistent at 2 days and
2 weeks. The rationale to do this was as follows. If a gene
in the WKY vs. SHR comparison was consistently
expressed differentially at 2 days and 2 weeks (but not at
48 weeks), this would support a potential role in early
development. We also evaluated whether differential
expression between WKY vs. SHR and SHR+ATCE vs.
SHR overlapped, reasoning that this would reflect “correc-
tion” of the SHR transcriptome. Genes differentially
expressed only in 48-week-old animals are most likely
related to age and/or evolving damage.
Analysis of frequency of binding sites for transcription
factors
To assess whether the genes expressed at different ages and
responsive to perinatal ATCE treatment had different
frequencies of transcription factor (TF) binding sites
(TFBS) in their promoter regions, the 1,000-bp upstream
regions of these genes were analyzed as previously
described [4]. First, the upstream sequence of 1,000 bp of
each gene was obtained via BIOMART (http://www.
biomart.org). This sequence was subjected to TFBS
analysis with a library of mononucleotide weight matrices
from TRANSFAC® 6.0 using MATCH™ [23]( http://www.
gene-regulation.com), and matrix and core similarity cut-
offs were set at 0.95. Two sets of genes were subjected to
this analysis: The differentially expressed genes and a set of
200 genes that was centered on a log2 ratio of zero. Thus,
for each experimental group, two sets of frequencies of
potential binding sites for TFs were obtained. A size test
was used to determine the significance in difference of
frequency of a TFBS between differentially expressed and
non-differentially expressed gene set at each age. The same
method for in silico analysis was applied to genes that were
consistently and consecutively differentially expressed in at
least two ages in WKY/SHR. This analysis was also
performed on genes in SHR+ATCE that were shifted
toward WKY level.
Quantitative PCR
For real-time PCR, total RNA from individual samples
(five to six per group) was used. Laboratory details on
semi-quantitative RT-PCR and the primer conditions are
available as Web Appendix (http://www.nephrogenomics.
net/data/appendices/SHR-Development/). TaqMan® Gene
Expression Assays (Applied Biosystems, Foster City, CA,
USA) were used for real-time quantitative PCR, and the
protocol was performed as recommended by the supplier. In
short, cDNA (50 ng of starting material total RNA) was
mixed with Taqman Universal PCR Master Mix (with
AmpErase UNG) and TaqMan® Gene Expression Assay in
end-volume of 25 μL. Quantitative PCR was performed
with the ABI 7900HT Fast Real-Time PCR System. Gene
threshold was determined by the SDS 2.2.2 software utility
(Applied Biosystems). Genes studied with quantitative PCR
were Cd36 (Rn00580728), connective tissue growth factor
(CTGF; Rn00573960), Ephx2 (Rn00576023), Gstm1
(Rn00755117), and Ptger2 (Rn00579419). Calculation of
the ratios is explained in the Web Appendix (http://www.
nephrogenomics.net/data/appendices/SHR-Development/).
All individual samples were compared to 2-day WKY as
the calibrator group.
Statistical analyses
Results are expressed as mean ± SEM. Group and age-
dependent effects were analyzed using two-way ANOVA
where appropriate followed by a Student–Newman–Keuls
post hoc test. The frequency of TFBS linked to differen-
tially expressed genes was compared to that of the same
TFBS linked to non-differentially expressed genes using the
size test. P<0.05 was considered significant.
Results
Animal data
The kidney/body weight (BW) ratio in SHR was higher
than in WKY at 2 days and 2 weeks but not at 48 weeks
(Table 1). Some of the kidneys at 48 weeks were from our
previous study [39]. At 48 weeks, systolic blood pressure
(measured every 4 to 6 weeks from age of 4 weeks) was
65–70 mmHg higher in SHR than in WKY (P<0.001). BW
was slightly lower in SHR+ATCE than in SHR at 2 and
48 weeks, but kidney/BW ratio was unaffected. At 2 days
and 2 weeks, 24-h urine collection was not yet possible. At
48 weeks, there were no difference in urine NOx and
TBARS between groups. In our previous study [39], we
found no difference in NOx and TBARS excretion from 20
weeks onward.
Global analysis of differential gene expression data
The number of differentially expressed genes at 2 days was
higher than at 2 weeks, both in WKY vs. SHR and in SHR
Pflugers Arch - Eur J Physiol (2009) 458:513–524 515+ATCE vs. SHR. The old rats showed the highest number
of differentially expressed genes (Table 2). As perinatal
treatment with ATCE may partially correct the renal
transcriptome in SHR, i.e., bring it closer to that of WKY,
WKY (vs. SHR), and SHR+ATCE (vs. SHR) were
compared using Venn diagrams. At 2 days and 2 weeks,
18 and nine of the differentially expressed genes (about
11%) were in the same direction in WKY and SHR+ATCE
respectively, while at 48 weeks, this applied to 28 genes
(about 7%). Hierarchical clustering was performed on the
Table 2 Number of differentially expressed genes
Number of differentially expressed genes
2 days 2 weeks 48 weeks Total
Criteria WKY/SHR SHR+ATCE/SHR WKY/SHR SHR+ATCE/SHR WKY/SHR SHR+ATCE/SHR
Induced 76 117 38 53 222 197 703
Reduced 45 46 56 35 272 143 597
Total 121 163 94
a 88
a 494
a 340
a 1,300
9
9
16
WKY SHR
+ATCE
4
5
11
WKY SHR
+ATCE
20
8
13
WKY  SHR
+ATCE
2 days old 2 weeks old
48 weeks old
55
32
104
25
28
46
43
25
194
259
172
127
Induced indicates a ratio >0.7; Reduced indicates a ratio <−0.7 Differences in the number of differentially expressed genes between ages were
determined using a z test. Venn diagrams compare differential expression of genes in WKY/SHR and SHR+ATCE/SHR. Upward and downward
arrows indicate up- and down-regulation, respectively. Symbiosis of upward and downward arrows indicates counter-regulation
aP<0.001 vs. all other ages with same treatment
Table 1 Animal data
aP<0.05 vs. WKY
bP<0.01 vs. WKY
cP<0.05 vs. SHR
WKY SHR SHR+ATCE
2 days old
n 66 6
Body weight (g) 4.3±0.3 4.8±0.1 4.4±0.2
Right kidney weight (mg) 21.3±3.0 28.5±1.4 27.0±2.1
RKW/BW (mg/g) 4.8±0.3 5.9±0.2
a 6.1±0.2
2 weeks old
n 65 5
Body weight (g) 29.9±0.5 20.4±0.2
b 17.0±1.8
c
Right kidney weight (mg) 150±2.5 121±1.9
b 98.2±8.7
c
RKW/BW (mg/g) 5.0±0.1 5.9±0.1
b 5.8±0.2
48 weeks old
n 81 2 6
Systolic blood pressure (mmHg) 122±2 187±6
b 176±5
c
Body weight (g) 267±9 254±8 228±4
c
Right kidney weight (mg) 968±53 882±27 784±32
RKW/BW (mg/g) 3.6±0.2 3.4±0.1 3.4±0.2
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how the groups related to each other (Fig. 1 in Web
Appendix).
This global analysis (both Venn diagram and clustering)
revealed that, vs. WKY, young SHR displayed less
differential renal gene expression than aged SHR. There
was little consistent differential expression between con-
secutive ages. Third, perinatal ATCE treatment resulted in
differential expression of the renal SHR transcriptome;
however, differential expression did not become similar to
WKY vs. SHR. Although at 48 weeks, perinatal ATCE in
SHR still had a profound impact on differential gene
expression (vs. control SHR); there was very little overlap
with differential gene expression in WKY vs. SHR.
(Non)consecutive differential expression of genes
at different ages
We first considered genes that were consistently differen-
tially expressed in WKY/SHR (Table 3; n=26). SHR was
chosen as the denominator, so that in Tables 3 and 4,
differential expression induced by perinatal treatment
Table 3 Genes consistently and consecutively differentially expressed at more than one age in WKY/SHR (n=26)
Symbol Description Control arrays 2 days 2 weeks 48 weeks
WKY SHR+ATCE WKY SHR+ATCE WKY SHR+ATCE
LOC171573 Spleen protein 1 precursor 0.0 −1.8 −0.1 −1.1 0.0 0.6 0.6
Cdk5rap1 CDK5 regulatory subunit associated
protein 1
−0.5 −1.0 0.5 −0.9 1.3 0.1 0.2
Grin3a Glutamate receptor, ionotropic,
N-methyl-d-aspartate 3A
0.0 −0.9 −1.0 −0.8 1.5 −0.9 −0.7
Ephx2 Epoxide hydrolase 2, cytoplasmic 0.0 −0.8 −0.1 −1.9 0.0 −1.4 0.1
Skiv2l Superkiller viralicidic activity 2-like −0.1 −0.7 0.1 −0.7 0.0 −0.2 0.3
Ctsl Cathepsin L 0.0 0.7 0.0 0.7 0.0 0.3 0.0
Gstm1 Glutathione-S-transferase −0.1 0.8 0.0 0.7 −0.1 −0.2 0.2
Psg19 Heart and neural crest derivatives
expressed transcript 1
−0.1 0.8 0.0 0.8 −0.1 0.2 0.0
Ptprj Protein tyrosine phosphatase,
receptor type, J
0.0 0.8 0.2 1.1 −0.1 1.0 0.2
Sval2 Seminal vesicle antigen-like 2 −0.1 0.9 1.1 0.9 0.0 0.2 0.0
V1rb5 Vomeronasal V1r-type receptor
V1rb5
0.0 0.9 −1.1 1.0 1.5 0.0 −0.3
RT1-N1 RT1 class Ib gene, H2-TL-like,
grc region (N1)
−0.1 1.0 0.0 1.1 0.1 0.3 0.1
Uts2r Urotensin 2 receptor 0.4 1.1 −1.7 1.9 0.2 0.1 0.3
Retsat All-trans-13,14-dihydroretinol
saturase
0.0 1.1 0.0 0.9 −0.1 1.3 0.0
Gabrr3 Gamma-aminobutyric acid (GABA)
receptor, rho 3
−0.1 1.4 0.2 1.3 0.4 −0.3 0.1
Nmi N-myc (and STAT) interactor −0.2 1.5 1.3 1.0 −0.4 0.9 0.4
Ptger2 Prostaglandin E receptor 2,
subtype EP2
−0.1 1.5 −0.7 0.8 −1.7 −0.3 0.1
Cfi Complement factor I 0.0 1.5 −0.6 1.2 0.1 −0.1 −0.4
Il2 Interleukin 2 −0.1 1.6 −0.2 1.0 0.2 −0.3 −0.2
Spp2 Secreted phosphoprotein 2 0.0 1.7 −0.4 0.9 0.1 0.7 0.3
Cd36 Cd36 antigen −0.1 2.8 0.9 1.5 −0.1 0.5 −0.2
RT1-Bb RT1 class II, locus Bb 0.0 −0.2 −0.1 −1.2 0.0 −3.4 −0.1
Adam6 A disintegrin and metallopeptidase
domain 6
0.0 0.1 0.1 −0.8 −0.1 −1.4 0.1
Ctgf Connective tissue growth factor 0.0 −0.4 0.5 −0.9 −0.3 −1.3 −0.1
Cd74 CD74 antigen (invariant polypeptide
of major histocompatibility complex,
class II antigen-associated)
0.0 −0.5 −0.1 −0.8 −0.1 −0.9 0.0
Adam18 A disintegrin and metallopeptidase
domain 18
0.2 −0.1 0.1 0.8 Below threshold 1.8 −0.1
Ratios in bold indicate absolute ratio >0.7
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consistently differentially expressed at 2 days and 2 weeks,
and six genes were consistently differentially expressed at
all three ages. Five other genes were consistently differen-
tially expressed at 2 weeks and 48 weeks. At 2 days and
2 weeks, two vascular receptors, prostaglandin E2 receptor
(Ptger2) and GABA receptor rho3 (Gabrr3), were higher in
WKY/SHR. At all ages, Ephx2 (soluble epoxide hydrolase),
Grin3a (glutamate receptor 3A), and Gstm1 (glutathione-S-
transferase) were consistently lower in WKY/SHR. At 2 and
48 weeks, CTGF and CD74 are lower in WKY/SHR.
Among the consistently differentially expressed genes in
WKY/SHR, 15 were also among the most strongly differen-
tially expressed genes (Web Appendix; Table 2).
We then focused on differential expression of genes
in SHR+ATCE/SHR that shifted toward WKY/SHR
levels. The Venn diagram showed that 55 genes had
congruent differential expression in both WKY and
SHR+ATCE as compared to SHR (Table 2; all ages
together). Only six of these 55 genes were shifted in the
same direction in at least two ages (consistent change). At
both 2 days and 2 weeks, this was the case for five genes,
namely two organic anion solute carriers (Slco1a1 and
Slco1a5), two cytochrome P450 oxidases (Cyp2c13 and
Cyp3a62), and a trypsin (Prss1; Table 4). At 48 weeks,
only one of the 28 genes, where differential expression of
SHR+ATCE/SHR had shifted toward WKY/SHR, coin-
cided with one of the six genes consistent changed by
Table 4 Genes differentially expressed in SHR+ATCE/SHR toward age-matched WKY/SHR level at 2 days (n=15) and 2 weeks (n=9)
Symbol Description Control arrays 2 days 2 weeks 48 weeks
WKY SHR+ATCE WKY SHR+ATCE WKY SHR+ATCE
Cyp2c13 Cytochrome P450 2c13 −0.2 −2.5 −2.4 1.2 −1.5 0.5 0.1
Cyp11b2 Cytochrome P450, family 11,
subfamily B, poly peptide 2
0.1 −2.3 −1.8 0.0 0.8 0.0 0.0
Cyp21a1 Cytochrome P450, subfamily 21A,
poly peptide 1
0.2 −1.8 −1.4 −0.1 −0.5 0.0 0.1
Cyp11b1 Cytochrome P450, subfamily 11B,
poly peptide 1
−0.1 −2.6 −1.4 −0.1 −0.3 0.1 −0.1
Grin3a Glutamate receptor, ionotropic,
N-methy l-D-aspartate 3A
0.0 −0.9 −1.0 −0.8 1.5 −0.9 −0.7
Atf3 Activating transcription factor 3 −0.1 −0.9 −1.0 0.3 0.1 0.1 −0.1
Akr1b7 Aldo-keto reductase family 1,
member B7
0.2 −1.2 −0.9 0.7 −0.1 0.6 0.2
Nr4a1 Nuclear receptor subfamily 4,
group A, member 1
0.0 −0.7 −0.9 0.0 0.3 1.1 −0.1
Cyp3a62 Cytochrome P450, subfamily 3A,
poly peptide 62
−0.2 1.0 0.7 −0.1 0.8 0.1 −0.3
Fut9 Fucosy ltransferase 9 0.2 1.7 0.7 0.5 −0.5 0.2 0.1
Ptgfr Prostaglandin F receptor 0.2 0.9 0.9 −1.3 0.3 0.0 −0.1
Cd36 Cd36 antigen −0.1 2.8 0.9 1.5 −0.1 0.5 −0.2
Sval2 Seminal vesicle antigen-like 2 −0.1 0.9 1.1 0.9 0.0 0.2 0.0
Cars Cysteinyl-tRNA synthetase −0.2 1.0 1.2 0.4 0.3 −0.1 0.3
Nmi N-my c (and STAT) interactor −0.2 1.5 1.3 1.0 −0.4 0.9 0.4
Ndufa12 NADH dehydrogenase (ubiquinone)
1 alpha subcomplex, 12
−0.5 1.3 −0.5 −0.8 −1.7 −0.2 −0.4
Hist1h4b Histone cluster 1, H4b 0.2 0.1 −0.2 −1.0 −1.3 0.0 −0.9
Prss1 Protease, serine, 1 (trypsin 1) −0.1 −0.3 −1.2 −0.8 −1.1 0.0 0.0
Slco1a1 Solute carrier organic anion
transporter family, member 1a1
0.1 −0.1 −2.5 −2.2 −1.1 0.9 0.1
Prl8a3 Prolactin family 8, subfamily a,
member 3
0.1 −0.4 0.0 −1.3 −0.8 0.0 0.4
Krt1 Keratin 1 0.1 −0.2 −0.3 1.2 0.8 −0.1 0.3
Slco1a5 Solute carrier organic anion
transporter family, member 1a6
0.2 0.1 1.6 1.1 1.0 0.1 0.1
Ryr2 Ryanodine receptor 2, cardiac 0.2 −0.5 −0.1 1.6 1.3 −0.1 0.5
V1rb5 Vomeronasal V1r-type receptor V1rb5 0.0 0.9 −1.1 1.0 1.5 0.0 −0.3
Ratios in bold indicate absolute ratio >0.7
518 Pflugers Arch - Eur J Physiol (2009) 458:513–524ATCE treatment at age of 2 days, namely the glutamate
receptor Grin3a.
Analysis of frequency of binding sites for transcription
factors
In an attempt to identify transcription factors involved in
the regulation of gene expression in the renal cortex of the
SHR at different ages, we performed an in silico analysis of
the 1,000 bp upstream regions of the differentially
expressed genes for the presence of TFBS and compared
this to the upstream regions of genes that were not
differentially expressed.
The first analysis describes the frequency, for each age,
with which a TFBS can be detected in a group of
differentially expressed genes vs. the non-differentially
expressed control set. Comparing upstream regions in
differentially expressed genes vs. non-differentially
expressed genes in WKY vs. SHR revealed 12 TFBS to
be significantly affected (Table 5). Only Elk-1 and S8 were
identified at both 2 days and 2 weeks, and Elk-1 was the
only TF with a reduced frequency of TFBS. Whether
reduced or induced frequency correlated with increased or
reduced gene differential expression in WKY vs. SHR is
undetermined because all genes were taken into the
calculation, and TF activity at TFBS can be both stimu-
latory and inhibitory.
In silico analysis of SHR+ATCE vs. SHR datasets
revealed eight TFBS to be involved. Interestingly, both
SHR+ATCE/SHR and WKY/SHR had reduced Elk-1
frequency at 2 days and 2 weeks, indicating that ATCE
treatment shifted Elk-1 frequency in SHR toward that of
WKY. The observation that the frequency of Elk-1 TFBS
was reduced in both WKY and SHR+ATCE vs. SHR
suggests that SHR have enhanced Elk-1 driven gene
transcription as compared to WKY at 2 days and 2 weeks.
Elk-1 was not identified by this approach at 48 weeks,
suggesting a specific role in the prehypertensive stage.
In the second analysis, we determined whether the genes
consistently and consecutively altered at different ages (at
all ages and at 2 days and 2 weeks in WKY/SHR) were
related to each other with respect to their TFBS. Four (CDP,
GATA-X, HFH-8, and XFD-2) had significantly altered
frequency of their TFBS (Table 6). Note that the reduction
of Elk-1 binding sites was not associated with consistently
differentially expressed genes. For genes differentially
expressed at all ages, TFBS for CDP were more frequent
at day 2. Both GATA-X and XFD-2 had TFBS with a
higher frequency at 2 days and 2 weeks for the genes with
consecutive differential expression in the 2 days to 2 weeks
gene set of WKY/SHR. For HFH-8, an increased frequency
of TFBS in differentially expressed genes was detected at
day 2 in the gene set of 2 days to 2 weeks of WKY/SHR.
Note that HFH-8 also appears in whole WKY/SHR data set
at 2 days (Table 5).
For each age, the TFBS level of differentially expressed
genes in SHR+ATCE/SHR that had shifted toward WKY/
SHR was determined (Table 6). Increased frequencies at
eight TFBS were found: five at 2 days, one at 2 weeks, and
two at 48 weeks. The TFBS for ER appeared in both
analyses (cf., Tables 5 and 6), but not at the same age.
Gene expression by PCR
Semi-quantitative PCR was performed on ten genes in 2-
days and 2-week-old SHR (Table 5; Web Appendix).
Quantitative PCR was performed on Cd36, Gstm1, Ephx2,
CTGF, and Ptger2 in WKY, SHR, and SHR+ATCE at all
ages. Note that, in contrast to differential expression of the
microarray data in Table 3, the data in Fig. 1 are normalized
to expression in WKY at 2 days. Due to deletion in Cd36
caused by unequal recombination [14], gene expression of
Table 5 Analysis of frequency of transcription factor binding sites
(TFBS) in WKY/SHR and SHR+ATCE/SHR
WKY/SHR SHR+ATCE/SHR
z test z test
TF 2
days
2
weeks
48
weeks
2
days
2
weeks
48
weeks
Elk-1 ↓↓ – ↓↓↓ ↓ –
S8 ↑↑ –– –↑↑
HFH-8 ↑ ––– ––
Tal-1alpha/E47 ↑ ––– ––
Tal-1beta/E47 ↑↑ ––– ––
GATA-1 – ↑ –– ––
GATA-2 – ↑ –– ––
GATA-X – ↑↑↑ –– ––
Lmo2 – ↑ –– ––
Poly – ↑ –– ––
HFH-1 –– ↑ –– –
HFH-3 –– ↑↑ –– –
c-Myc/Max –– – ↓ ––
c-Rel –– – ↓ ––
NRF-2 –– – ↓ ––
ER – ––– –↑
HNF-3beta – ––– –↑↑
HNF-4 – ––– –↑
For each experimental group, two sets of frequencies of potential
TFBS were obtained (differentially expressed and non-differentially
expressed genes). Note that frequency was either up or down. A size
test was applied to determine the significance in difference of
frequency of a TFBS between the differentially expressed and non-
differentially expressed genes (one, two, or three arrows indicate P<
0.05, P<0.01, and P<0.001, respectively). Reduced/increased fre-
quency indicates that the binding site is less/more frequently activated
or is inhibited/stimulated, respectively
↓ reduced frequency, ↑ increased frequency
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Gstm1 gene expression was reduced in SHR compared to
WKY at all ages (Fig. 1a). ATCE treatment in SHR
temporarily induced Gstm1 to the level of WKYat 2 weeks.
Ephx2 gene expression was strongly increased in SHR as
compared to WKY at all ages, confirming that the micro-
array data and ATCE treatment induced the expression
slightly more at 2 and 48 weeks (Fig. 1b). CTGF and
Ptger2 were increased in SHR vs. WKY (all ages for CTGF
and 48 weeks for Ptger2) but were not consistently affected
by perinatal ATCE treatment (Figs. 1c and d).
Discussion
Extensive differential expression involving hundreds of
genes was present at a very early age, namely 2 days and
2w e e k s ,i nS H Rv s .W K Y .H o w e v e r ,ar e l a t i v e l ys m a l l
group of these displayed consistent and consecutive
differential expression at 2 days and 2 weeks. The renal
transcriptome also varied substantially at different ages
for SHR+ATCE vs. SHR, suggesting both direct and
indirect effects of early treatment. However, perinatal
treatment of SHR with ATCE induced practically no
congruent direct change in differential expression for the
two comparisons. In silico analysis of TFBS for both sets
of differentially expressed genes revealed that only ELK-
1 was consistently related to differentially expressed
genes in both comparisons and at both 2 days and
2 weeks. At 48 weeks, there were very few genes with
congruent differential expression in the two comparisons
a n dn os h a r e dT F B S .
Differential renal gene expression was quite extensive at
2 days and 2 weeks. Because of our interest in early
development of hypertension, this was the focus of our
attention. In the light of the perinatal intervention with
ATCE, we first investigated the transporters of L-arginine
and taurine, as reported elsewhere [24]. The expression of
Slc7a7 (an important basolateral arginine transporter) was
decreased in 2 days SHR vs. WKY, and RT-PCR revealed
slc7a7 also to be decreased in 2 weeks SHR. This suggests
defective renal arginine transport, which may be related to
the reduced renal NO production that we recently docu-
mented in 2-week-old female SHR [24]. The present study
shows that ATCE supplements did not affect slc7a7
expression in SHR (Web Appendix, Table 5). Hence,
perinatal ATCE may not directly be able to improve renal
nitric oxide (NO) production, and the increased renal NO
observed previously [39] may have resulted from decreased
oxidative stress. Another gene of interest was soluble
(cytoplasmic) epoxide hydrolase 2 (Ephx2), an enzyme
that metabolizes epoxyeicosatrienoic acids, potent vasodi-
lator agents, to less active dihydroxyeicosatrienoic acids
[21]. Inhibition of Ephx2 has been shown to reduce blood
pressure in various models of hypertension [20]. Our
finding that Ephx2 was consistently and strongly upregu-
lated from 2 days of age makes it an obvious target for
inhibition at an early age, and these experiments are indeed
underway. However, Ephx2 was not inhibited by ATCE, on
the contrary.
Table 6 Analysis of frequency of transcription factor binding sites (TFBS) in WKY/SHR that are linked to consistently and consecutively
differentially expressed genes and in SHR+ATCE/SHR that are linked to genes differentially expressed either up or down
All ages in WKY/SHR 2 days and 2 weeks in WKY/SHR SHR+ATCE/SHR shifted toward age-matched WKY/SHR
z test z test z test
TF 2 days 2 weeks 48 weeks 2 days 2 weeks 2 days 2 weeks 48 weeks
CDP ↑ –– – – – – –
GATA-X –– – ↑↑ ↑–– –
HFH-8 –– – ↑ –– – –
XFD-2 –– – ↑↑ ↑↑ –– –
ER –– – – – ↑↑ ––
GATA-3 –– – – – ↑ ––
Gfi-1 –– – – – ↑ ––
RFX1 –– – – – ↑ ––
TGIF –– – – – ↑ ––
GR –– – – – – ↑↑ –
Oct-1 –– – – – – – ↑
XFD-1 –– – – – – – ↑↑
A size test was applied to determine the difference of frequency of a TFBS between the differentially expressed and non-differentially expressed
genes (one or two arrows indicate P<0.05 and P<0.01, respectively). Increased frequency indicates that the binding site is more frequently
activated or is stimulated
↑ increased frequency
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SHR include fatty acid translocase (Cd36) and glutathione-
S-transferase (Gstm1). Cd36 was identified as an insulin-
resistance gene causing defective fatty acid and glucose
metabolism in SHR [1]. This is due to deletion in Cd36
caused by unequal recombination [14]. Our amplification
plot of qPCR clearly confirms the existence of different
gene products of Cd36 in WKY and SHR. Transgenic
rescue of defective Cd36 prevents insulin resistance but not
high blood pressure [38]. Moreover, the Cd36 mutation was
absent in the original SHR [15, 35]. However, a recent
report from the same group does implicate Cd36 in the
pathogenesis of hypertension in SHR [37]. Prevention of
oxidative stress may ameliorate development of hyperten-
sion in SHR [40, 48, 49]. Oxidative stress is increased in
the kidney of aging SHR [6, 12]. This has been ascribed to
the well-documented reduced expression of Gstm1 [19, 32,
33]. However, similarly to Cd36, earlier work has shown
that down-regulation of Gstm1 is not common to all SHR
substrains [35]. Moreover, recent data document that
GSTM variants are not associated with hypertension in
humans [8]. Thus, for Gstm1, convincing evidence
suggests relations with the metabolic but not the hyper-
tensive aspects of the SHR phenotype. Neither Cd36 nor
Gstm1 was substantially directly or indirectly affected by
perinatal ATCE in SHR, despite persistently reduced
blood pressure [39].
TFs importantly regulate transcription [27]. Conversely,
a gene expression profile may indirectly reflect the actions
of TFs. Therefore, TFs can be related to differentially
expressed genes in WKY vs. SHR and in SHR+ATCE vs.
SHR. We previously developed an approach to derive
potential TFBS from a differential gene expression set [4].
While we recognize the limitations of such a screening
approach, it can lead us to TFs that are involved in both the
development of hypertension and in perinatal programming
phenomena in the SHR. The generated inventory of
documented TFBS, recognized in the upstream 1,000 bp
of the differentially expressed vs. non-differentially
expressed genes, revealed that only binding sites of
Elk-1 are significantly less associated with differential
gene expression between WKY and SHR and between
SHR+ATCE and SHR. This was observed at 2 days and at
2 weeks. The observation that the frequency of Elk-1 TFBS
was reduced in both WKY and SHR+ATCE vs. SHR
suggests that untreated SHR have enhanced Elk-1 driven
gene transcription at 2 days and 2 weeks. Elk-1 is
reportedly down-stream of ERK 1/2, MAPK, and JNK
(Fig. 2; Web Appendix) [13, 28]. Down-stream signaling
from Elk-1 is via c-Fos and other pathways [44]. With
respect to the treatment with arginine and antioxidants, it
could be noted that ERK1/2 is influenced by NO through
cAMP [5, 18] and JNK and Elk-1 by NO and ROS [22].
Very little information is available on the role of epigenetic
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Fig. 1 Real-time quantitative
PCR of Gstm1 (a), Ephx2 (b),
CTGF (c), and Ptger2 (d). There
were five to six rats per group.
All data are expressed relative to
WKY at 2 days. Data were
analyzed by two-way ANOVA.
Different degrees of post hoc
significances are all collected in
P<0.05 in order to decrease
complexity of presentation.
#P<0.05 vs. WKY (same age),
*P<0.05 vs. SHR (same age),
†P<0.05 vs. younger age (same
strain)
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recently, it was reported that intrauterine growth retardation
is associated with progressive epigenetic silencing of Pdx1,
a pancreatic and duodenal homeobox 1 TF that regulates
pancreas development and β cell differentiation [36].
Ultimately, this appears to lead to the development of type
2 diabetes in adults [42]. However, in our model, Elk-1
binding sites are not significantly linked to individual genes
that were consistently differentially expressed at more than
one age, underlining the complexity of transcriptional
regulation down-stream from Elk-1.
In SHR vs. WKY, the number of differentially expressed
genes increased fivefold from 2 to 48 weeks. Changes in
our study were less consistent than previously reported
[19]. This is not unexpected because the age span in that
study was only from 4 to 18 weeks [19], which falls within
the 2- to 48-week step in our study. This supports the
notion that in the face of persistent hypertension, secondary
changes occur in the renal cortex and in other target organs
[11, 47]. However, with respect to our secondary objective,
we could identify very few persistent consistent changes in
differential gene expression in the WKY/SHR gene set, and
none of these were affected by perinatal ATCE. The latter is
possibly due to the fact that perinatal ATCE only reduced
systolic blood pressure by about 35 mmHg between 14 and
26 weeks and that this difference fell to about 10 mmHg by
48 weeks. This is similar to the reduction obtained by
continuous antioxidant supplements administered from the
first week of pregnancy up to 24 weeks of age [48, 49].
Moreover, there were no persistent TFBS. Had we observed
multiple persistent and consistent changes, then we would
sorely have missed a group of WKYperinatally treated with
ATCE. However, for the current data set, this does not
appear to be a major drawback. An interesting gene in the
light of aging, hypertension, and target organ damage is
CTGF. Although CTGF is widely studied, little is known
on renal CTGF in SHR. CTGF is induced in adult SHR and
is reduced by antihypertensive treatments [7], suggesting
that CTGF expression is dependent on blood pressure.
However, we already found increased CTGF expression at
2 days in SHR, a stage when presumably no hypertension,
let alone fibrosis, is present.
Some limitations of the present study have to be
discussed. First, the kidney is highly inhomogeneous.
However, there was no a priori reason to choose a single
structure (e.g., only glomeruli), so no differential sieving
was applied. Moreover, histology confirmed that there were
no differences in renal morphology between WKY and
SHR. Thus, cortex was sampled from all the adult rats by
sampling the renal poles. However, in the small pups,
separation of cortex and medulla was not clear. Thus, all or
half of the kidney was taken from 2-day and 2-week-old
rats, respectively. This ensured that the degree of homoge-
neity remained constant between age-matched SHR and
WKY. Second, an absolute stringent cutoff of 0.7, much
higher than three times the standard deviation of the six
control-vs.-control arrays, was applied to identify differen-
tial gene expression. Applying the stringent cutoff lowers
the chance of false positives, but subtle changes in
differential gene expression may be missed. Lastly, micro-
array technology is extremely powerful but is not a
technology that is easily applicable to test mechanisms, in
particular not when considering the complex structure of
the kidney. Nevertheless, there are numerous other micro-
array studies, which have pointed at potential mechanisms,
and then have been followed by studies specifically
directed at these potential pathways, including one from
our group [24].
In conclusion, analysis of the renal transcriptome over
the whole life span of WKY and SHR+ATCE vs. SHR
revealed considerable differential expression from a very
early age, but with very little overlap. The number of
differentially expressed genes increases with age, suggest-
ing secondary changes. At an early age, a common factor to
both sets of differentially expressed genes was a reduction
in TFBS of Elk-1. Our genomics approach suggests
increased activity of the TF ELK-1 in SHR in the
prehypertensive stage. This deserves further study.
Perspective
There is accumulating evidence that poor conditions in early
life have long-term deleterious consequences, including
hypertension [34]. The present study shows that perinatal
treatment of hypertensive rats with micronutrients such as
amino acids and vitamins that persistently lowered blood
pressure in their offspring directly affects the renal cortical
transcriptome. As such, improved conditions in early life
may have long-term advantages, especially in people with a
predisposition to hypertension such as indigenous commu-
nities exposed to a Western life style [3, 45].
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